

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

SUNDAY, MAY 3, 2026

15:00 *Welcome Coffee & Registration*

15:30 – 16:55 **SYMPOSIUM HOSTED BY THE DRAVET SYNDROME FOUNDATION OF SPAIN (SESSION I)**

Chairs: **Jose Ángel Aibar, Madrid, Spain**
Emilio Perucca, Melbourne, Australia

15.30 **OPENING STATEMENTS**

15.40 THE NEUROBIOLOGY OF COMORBIDITIES IN DRAVET SYNDROME
Moran Rubinstein, Tel-Aviv, Israel

16.05 ADDRESSING GAPS IN GENETIC TESTING FOR DRAVET SYNDROME
Andreas Brunklaus, Glasgow, UK

16.30 UNDERSTANDING DISEASE MODIFICATION AND SYMPTOMATIC TREATMENTS FOR DRAVET SYNDROME
Simona Giorgi, Elche, Spain

16:55 *Coffee Break*

17:15 – 18:30 **SYMPOSIUM HOSTED BY THE DRAVET SYNDROME FOUNDATION OF SPAIN (SESSION II)**


Chairs: **Jose Ángel Aibar, Madrid, Spain**
Torbjörn Tomson, Stockholm, Sweden

17.15 OUTCOME MEASURES: "SEIZURES AND NON-SEIZURES" IN CLINICAL TRIALS OF TREATMENTS FOR DEEs
Elaine Wirrell, Rochester, USA

17.40 THE IMPORTANCE OF MULTIDISCIPLINARY MANAGEMENT IN DEEs
Stéphane Auvin, Paris, France

18.05 PATIENT-CENTERED HEALTHCARE: THE POWER OF PATIENT ADVOCACY
José Ángel Aibar, Madrid, Spain

18.30 **CLOSING REMARKS**



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026

08:15 – 08:30

OPENING SESSION

ORGANIZING COMMITTEE REMARKS AND GREETINGS

Meir Bialer, *Organizing Committee, Jerusalem, Israel*

GREETINGS

Emilio Perucca, *Organizing Committee and ILAE Past-President, Melbourne, Australia*

08:30 – 10:30

Session 1: PRECLINICAL MODELS OF DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs): FROM SYMPTOMATIC TREATMENT TO DISEASE-MODIFYING AND PREVENTIVE STRATEGIES

Chairs: **Heidrun Potschka**, *Munich, Germany*

Gabriele Lignani, *London, UK*

08:30

FACE AND PREDICTIVE VALIDITY OF DEE MODELS: BASIS FOR ROBUST ASSESSMENT OF ANTISEIZURE EFFECTS

Heidrun Potschka, *Munich, Germany*

08:50

Discussion

09:00

IT'S NOT ALL ABOUT SEIZURES: ASSESSMENT OF EFFECTS ON NON-SEIZURE SYMPTOMS IN DEE MODELS

Moran Rubinstein, *Tel-Aviv, Israel*

09:20

Discussion

09:30

PRECISION MEDICINE APPROACHES FOR DEEs: TESTING STRATEGIES CONSIDERING

SPECIES DIFFERENCES AND THE INFLUENCE OF GENETIC VARIANTS

Jack M. Parent, *Ann Arbor, USA*

09:50

Discussion

10:00

THE EARLIER – THE BETTER? - ASSESSMENT OF POSSIBLE DISEASE-MODIFYING AND PREVENTIVE STRATEGIES IN DEE MODELS


Gabriele Lignani, *London, UK*

10:20

Discussion

10:30

Coffee Break



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026, (Cont.)

11:00 – 13:00 Session 2: NEW THERAPEUTIC AGENTS IN DEVELOPMENT


Chairs: **Meir Bialer**, Jerusalem, Israel
Emilio Perucca, Melbourne, Australia

- 11:00 AUT00206
Charles Large, Autifony Therapeutics, UK
- 11:20 Discussion
- 11:30 BEXICASERIN (LP352)
Tolga Uz, Lundbeck Pharmaceuticals, Denmark
- 11:50 Discussion
- 12:00 PTI 5803
Panntherapi, France
Presented by **Gill Huberfeld**, Hôpital Fondation Adolphe de Rothschild, France
- 12:20 Discussion
- 12:30 RELUTRIGINE
Raquel Miralles, Praxis Precision Medicines, USA
- 12:50 Discussion
- 13:00 Lunch Break
-

14:15 – 16:15 Session 3: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Piero Perucca**, Melbourne, Australia
Elaine Wirrell, Rochester, USA

- 14:15 BMB-101
Stephen Collins, Bright Minds Biosciences, USA
- 14:35 Discussion
- 14:45 Elsunersen
Raquel Miralles, Praxis Precision Medicines, USA
- 15:05 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA


MONDAY, MAY 4, 2026, (Cont.)

- 15:15 EPX -100
Amit Ray, Harmony Biosciences, USA
- 15:35 Discussion
- 15:45 ES-481
ES-Therapeutics, USA
Presented by **Emma Foster, Monash University, Australia**
- 16:05 Discussion
- 16:15 Coffee Break

16:45 – 18:45 Session 4: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Cecilie Johannessen Landmark, Sandvika, Norway**
 Mathias Koepp, London, UK

- 16:45 ETX101
Joseph Sullivan, Encoded Therapeutics, USA
- 17:05 Discussion
- 17:15 ION283 ASO
Soud Messahel, Elpida Therapeutics, USA
- 17:35 Discussion
- 17:45 MSCA-7136
Brad Galer, Mosaica Medicines, USA
- 18:05 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

TUESDAY, MAY 5, 2026

08:15 – 10:15 Session 5: NEW THERAPEUTIC AGENTS IN DEVELOPMENT


Chairs: **Torbjörn Tomson, Stockholm, Sweden**
 H. Steve White, Seattle, USA

- 08:15 NRTX-1001
 Eduardo Dunayevich, Neurona Therapeutics, USA
- 08:35 Discussion
- 08:45 Opakalim (BHV-7000)
 Vivian Suarez, Biohaven Pharmaceuticals, USA
- 09:05 Discussion
- 09:15 OV329
 Julia Tsai, Ovid Therapeutics, USA
- 09:35 Discussion
- 09:45 PreVep-006 (SELETRACETAM)
 PreVep, USA
 Presented by **Wolfgang Löscher, Hannover Medical School, Germany and PreVep, USA**
- 10:05 Discussion
- 10:15 *Coffee Break*

10:45- 12:15 Session 6: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Meir Bialer, Jerusalem, Israel**
 Elaine Wirrell, Rochester, USA

- 10:45 RADIPRODIL
 Russell L. Chin, GRIN Therapeutics, USA
- 11:05 Discussion
- 11:15 RAP 219
 Willam Motley, Rapport Therapeutics, USA



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

TUESDAY, MAY 5, 2026, (Cont.)

11:35 Discussion

11:45 SIMUFILAM
Joseph Hulihan, Filana Therapeutics, USA

12:05 Discussion

12:15 Lunch Break

13:30 - 15:30 Session 7: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Cecilie Johannessen Landmark, Sandvika, Norway**
J. Helen Cross, London, UK

13:30 SN-2000
Deborah M Kurrasch, Stream Neuroscience Inc, Canada

13:50 Discussion

14:00 SODIUM SELENATE
Terence O'Brien, Monash University, Australia

14:20 Discussion


14:30 SVG103
Sovargen Co, Republic of Korea
Presented by **Hing-Ho Lee, Korea Advanced Institute of Science and Technology (KAIST)**
and **Sovargen Co, Republic of Korea**

14:50 Discussion

15:00 SYNGAP 1 ASO (CMP-002)
Yuri Maricich, CAMP4 Therapeutics, USA

15:20 Discussion

15:30 *Coffee Break*



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

TUESDAY, MAY 5, 2026, (Cont.)

16:00 – 17:00 Session 8: NEW THERAPEUTIC AGENTS IN DEVELOPMENT


Chairs: **Emilio Perucca**, Melbourne, Australia
Terence O'Brien, Monash University, Australia

- 16:00 VORMATRIGINE (PRAX-628)
Presented by **Raquel Miralles**, Praxis Precision Medicines, USA and
Angel Aledo-Serrano Clinical Neuroscience Institute (Blua Sanitas Valdebebas Hospita), Spain
- 16:20 Discussion
- 16:30 ZOREVUNERSEN
Carolyn Reeve, Biogen, USA
- 16:50 Discussion

17:00 – 18:00 Session 9: INNOVATIVE ROUTES OF RESCUE MEDICATION

Chairs: **Meir Bialer**, Jerusalem, Israel
Federico Vigevano, Rome, Italy

- 17:00 DIAZEPAM NASAL SPRAY
Stella Ngo, Neurelis, USA
- 17:20 Discussion
- 17:30 PRECLINICAL AND CLINICAL EVIDENCE IN SUPPORT OF A DISEASE MODIFYING EFFECT
OF DIAZEPAM TREATMENT ON SEIZURE CLUSTERS
Presented by **Steve White**, School of Pharmacy, University of Washington, USA
- 17:50 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

WEDNESDAY, MAY 6, 2026


08:15 – 09:15 Session 9: INNOVATIVE ROUTES OF RESCUE MEDICATION cont.

- 08:15 BUCCAL MIDAZOLAM
Neuraxpharm, Spain
Presented by **Federico Vigevano, IRCCS San Raffaele and LUMSA University, Italy**
- 08:35 Discussion
- 08:45 STACCATO ALPRAZOLAM
Robert Roebing, UCB Pharma, Belgium
- 09:05 Discussion
-

09:15-11:45 Session 10: PROGRESS REPORT ON RECENTLY MARKETED ANTISEIZURE MEDICATIONS

Chairs: **Cecilie Johannessen Landmark, Sandvika, Norway**
Emilio Perucca, Melbourne, Australia

- 09:15 BRIVARACETAM
Brian Moseley, UCB Pharma, Belgium
- 09:35 Discussion
- 09:45 CENOBAMATE
John Paul Leach, Angelini Pharma Group, Italy
- 10:05 Discussion
- 10:15 Coffee Break
- 10:45 FENFLURAMINE
Brian Moseley, UCB Pharma, Belgium
- 11:05 Discussion
- 11:15 GANAXOLONE
Immedica Pharma, Sweden
Presented by **Nicola Specchio, Bambino Gesù, Children Hospital, IRCCS, Italy**
- 11:35 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

WEDNESDAY, MAY 6, 2026 (Cont.)

11:45-13:15 Session 11: PROGRESS REPORT ON RECENTLY MARKETED ANTISEIZURE DEVICES

Chairs **Mathias Koepp**, *London, UK*
Piero Perucca, *Melbourne, Australia*

- 11:45 FOCAL CORTEX STIMULATION
Precisis, Germany
Presented by **Andreas Schulze-Bonhage**, *University of Freiburg, Germany*
- 12:05 Discussion
- 12:15 RESPONSIVE NEUROSTIMULATION
Martha Morrell, *Neuropace, USA*
- 12:35 Discussion
- 12:45 VAGUS NERVE STIMULATION
Maxine Dibué-Adjei, *LivaNova, UK*
- 13:05 Discussion
- 13:15 Lunch Break
-

14:30 – 17:00 Session 12: DEVELOPING STATE-OF-THE-ART THERAPIES FOR DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs)

Chairs: **Andreas Brunklaus**, *Glasgow, UK*
Elaine Wirrell, *Rochester, USA*

- 14:30 SELECTING POPULATIONS FOR TRIALS OF ANTISEIZURE MEDICATIONS (ASMs) FOR DEEs – SHOULD WE LUMP OR SPLIT?
Elaine Wirrell, *Rochester, USA*
- 14:50 Discussion
- 15:00 MEASURING NONSEIZURE OUTCOMES IN CLINICAL TRIALS IN DEEs
J. Helen Cross, *London, UK*
- 15:20 Discussion
- 15:30 WHAT IS MEANT BY “DISEASE MODIFYING” AND HOW DO WE PROVE THAT?
Stephane Auvin, *Paris, France*
- 15:50 Discussion

